Related Experiment Video
Updated: Mar 6, 2026

A Simple Pit Assay Protocol to Visualize and Quantify Osteoclastic Resorption In Vitro
Published on: June 16, 2022
[Effect of zoledronate on protein interaction between Ca(2+)/calmodulin-dependent protein kinaseⅡ and calmodulin and
1Department of Oral and Maxillofacial Surgery, College of Stomatology, North China University of Science and Technology, Tangshan Hebei 063000, China.
Abstract:
Objective: To investigate the effect of zoledronate on protein interaction between Ca(2+)/calmodulin-dependent protein kinaseⅡ(CaMKⅡ) and calmodulin and protein expression of nuclear factor of activation of T cells-1 (NFATc1) and tartrate resistant acid phosphatase (TRAP) during osteoclast differentiation. Methods: Mouse RAW264.7 cells were divided into group A and B and were cultured. Group A was induced with 50 mg/L receptor activator of NF-κB ligand (RANKL) for osteoclastogenesis, and group B was treated with 1×10(-6) zoledronate for two days from day 2. Co-immunoprcipitation (Co-IP) and reverse Co-IP were used to detect the protein-binding between CaMKⅡ and calmodulin. Western-blotting and immunofluorescent cytochemistry were also used to detect the protein level of NFATc1 and TRAP in both groups. Osteoclast formation was also analyzed. Results: In group B, the number of osteoclasts, number and size of dentin resorption lacunaes were 11.3±1.5, 8.7±2.1 and (5 034.4±775.4) μm(2) respevtively, which were significantly lower than those (37.7±5.7, 23.0±4.0 and [15 042.7±1 906.0] μm(2)) in group A (P<0.01). Co-IP and reverse Co-IP examination indicated that protein-binding between CaMKⅡ and calmodulin significantly decreased by 59.8% and 50.9% in group B compared with group A (P<0.01). The protein level of calmodulin and CaMKⅡ in total cellular proteins also significantly decreased by 52.1% and 51.5% in group B compared with group A (P<0.01). NFATc1 and TRAP protein decreased by 52.4% and 38.9% in group B than in group A (P<0.01), respectively. Conclusions: Zoledronate could significantly inhibit protein-binding between CaMKⅡ and calmodulin and down-regulate protein level of NFATc1 and TRAP.
Insights
Zoledronate significantly reduces osteoclast formation by inhibiting protein interactions between Ca(2+)/calmodulin-dependent protein kinase II (CaMKⅡ) and calmodulin. This drug also decreases the expression of nuclear factor of activated T-cells-1 (NFATc1) and tartrate-resistant acid phosphatase (TRAP).
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Osteoclast differentiation is crucial for bone remodeling and is implicated in various bone diseases.
- Ca(2+)/calmodulin-dependent protein kinase II (CaMKⅡ) and calmodulin play a role in cellular signaling pathways.
- Nuclear factor of activated T-cells-1 (NFATc1) and tartrate-resistant acid phosphatase (TRAP) are key markers of osteoclast differentiation.
Purpose of the Study:
- To investigate the inhibitory effects of zoledronate on osteoclast differentiation.
- To examine the impact of zoledronate on the protein interaction between CaMKⅡ and calmodulin.
- To assess the influence of zoledronate on the protein expression of NFATc1 and TRAP.
Main Methods:
- Mouse RAW264.7 cells were cultured and divided into two groups: one induced for osteoclastogenesis with RANKL, and another treated with zoledronate.
- Co-immunoprecipitation (Co-IP) and reverse Co-IP were employed to analyze CaMKⅡ and calmodulin protein binding.
- Western blotting and immunofluorescent cytochemistry were used to quantify NFATc1 and TRAP protein levels, alongside osteoclast formation analysis.
Main Results:
- Zoledronate treatment significantly reduced the number of osteoclasts and dentin resorption lacunae compared to the control group.
- Protein-protein binding between CaMKⅡ and calmodulin was significantly inhibited by zoledronate.
- Zoledronate significantly decreased the protein levels of CaMKⅡ, calmodulin, NFATc1, and TRAP.
Conclusions:
- Zoledronate effectively inhibits osteoclast differentiation.
- The drug's mechanism involves disrupting the CaMKⅡ-calmodulin protein interaction.
- Zoledronate down-regulates key osteoclastogenic factors, including NFATc1 and TRAP.
More Related Videos
08:53Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
Published on: January 1, 2017
11:47A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
Related Concept Videos
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
Osteoclasts in Bone Remodeling
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...